Drug data last refreshed 4h ago · AI intelligence enriched 5d ago
ELASE-CHLOROMYCETIN is a topical antibiotic ointment combining chloramphenicol (broad-spectrum antibiotic), desoxyribonuclease (enzymatic debridement agent), and fibrinolysin (fibrin-dissolving enzyme). It is indicated for wound care and infected skin conditions where enzymatic debridement and antimicrobial activity are therapeutically beneficial. The combination mechanism leverages both antibiotic and enzymatic action to promote wound healing.
With LOE approaching and no modern biosimilar or generic threats reported, the brand faces legacy product management challenges; teams are typically lean and focused on retention.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ELASE-CHLOROMYCETIN offers minimal growth trajectory but provides legacy product management experience and customer relationship expertise in niche wound care. This role suits professionals seeking stable, lower-pressure positions or those gaining foundational commercial skills before transitioning to growth-stage assets.
Worked on ELASE-CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.